Skip to content

Clinical trials

Infertility trials in China with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Infertility Phase: Not applicable Country / region: China Clear all

60 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20102
20124
20131
20145
20153
20163
20174
20186
20193
20205
20211
20224
20232
20246
20258
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed21
Unknown status16
Recruiting12
Terminated6
Not yet recruiting3
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Reproductive & Genetic Hospital of CITIC-Xiangya7
The University of Hong Kong7
Peking University Third Hospital4
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University4
Northwest Women's and Children's Hospital, Xi'an, Shaanxi3
Professor Ernest Hung-Yu Ng3
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School3
The Third Xiangya Hospital of Central South University3
Chenshiling2
ShangHai Ji Ai Genetics & IVF Institute2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Infertility60
Gynatresia4
Polycystic Ovary Syndrome4
Abortion, Spontaneous2
Infertility, Female2
Ovarian Hyperstimulation Syndrome2
Aneuploidy1
Anxiety Disorders1
Chromosome Aberrations1
Genetic Diseases, Inborn1

Trials

Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.